AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research

27-Jul-2011 - Germany

MorphoSys AG announced that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.

"We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances